JR-AB2-011

JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM) [1].JR-AB2-011 decreases the phosphorylation level of Akt, decreases MMP2 activity, thereby reducing the ability of tumor cells to migrate and invade. JR-AB2-011 also induces non-apoptotic cell death[2].

Product Specifications

CAS Number

[2411853-34-2]

UNSPSC

12352005

Target

MTOR

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/JR-AB2-011.html

Purity

98.15

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

ClC1=C(Cl)C=C(NC(N2/C(SC(C)C2)=N/C3=CC=C(F)C=C3)=O)C=C1

Molecular Formula

C17H14Cl2FN3OS

Molecular Weight

398.28

References & Citations

[1]Zhang A, et al. CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats. Stroke Vasc Neurol. 2022 Jul 26;8 (1) :4–16.|[2]Guenzle J, et al. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int J Mol Sci. 2020 Dec 22;22 (1) :30|[3]Wu M, et al Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res. 2021 Oct ; 172:105796